#DidYouKnow? More than 40% of all cancers diagnosed in the U.S. and nearly half of all deaths from cancer can be attributed to preventable causes such as excessive exposure to the sun, smoking, excess body weight, and physical inactivity (via American Association for Cancer Research). #CancerPreventionMonth
Castle Biosciences, Inc.
Biotechnology Research
Friendswood, Texas 10,506 followers
Improving health through innovative tests that guide patient care
About us
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people first—the patients who benefit from the information that our advanced diagnostic tests provide, the clinicians who use our tests to guide disease management decisions, our talented and valued employees, and our investors. Our innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. We currently market six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, uveal melanoma, Barrett’s esophagus, and mental health. https://castletestinfo.com Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. http://bit.ly/DDx-Melanoma DecisionDx®-SCC is our GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. https://bit.ly/DDx-SCC DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. https://bit.ly/DDx-UM Our comprehensive diagnostic offering — myPath® Melanoma and DiffDx®-Melanoma — provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. https://bit.ly/myPathDiffDx TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. https://tissuecypher.com Castle Biosciences is based in Friendswood, TX and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.
- Website
-
http://www.castlebiosciences.com
External link for Castle Biosciences, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Friendswood, Texas
- Type
- Public Company
- Founded
- 2008
- Specialties
- Diagnostic Cancer Testing, Uveal Melanoma, Cutaneous Melanoma, Melanoma, Skin Cancer, Next Gen Sequencing, Cutaneous Squamous Cell Carcinoma, Gene Expression Profile Tests, Barrett's Esophagus, Esophageal Adenocarcinoma, and Dermatologic Cancer
Locations
-
Primary
505 S Friendswood Dr
Suite 401
Friendswood, Texas 77546, US
-
3737 N 7th St
Suite 160
Phoenix, Arizona 85014, US
-
235 William Pitt Way
B1
Pittsburgh, Pennsylvania 15238, US
Employees at Castle Biosciences, Inc.
-
Matthew Turner
-
Kathleen Irwin
Corporate Communications Manager at Castle Biosciences, Inc.
-
Vicki Fish
Experienced biotech executive with proven success- commercialization, sales management, leading high performance teams.
-
Ross P. Sutcliffe
Award-Winning Sales and Marketing Professional With Experience, Passions for Partnership Creation, and Advancing the Standard of Care In Mental Health
Updates
-
Now published in AJMC - The American Journal of Managed Care: 40-GEP Test Utilization Can Mitigate Financial Burden of Cutaneous Squamous Cell Carcinoma Patients with cutaneous squamous cell carcinoma (cSCC) would save substantially on Medicare costs with the use of the DecisionDx-SCC 40-gene expression profile (40-GEP) test to inform decisions regarding adjuvant radiation therapy (ART), according to a recent study published in Journal of Clinical and Aesthetic Dermatology. More: https://hubs.la/Q02jxFf00
-
-
📢 NEW publication in JDPA titled, “Genomics in dermatology/precision medicine-more than sequence” by Love et al. The publication reviews available genomic tests in dermatology and how they can be utilized in clinical practice, including, but not limited to MyPath Melanoma, DecisionDx-Melanoma and DecisionDx-SCC. It reviews how other fields of medicine have been trailblazers of genomic technology, and how the field of genomics is truly novel with a bright future in dermatology. Read more here: https://hubs.la/Q02jlNw60 #GenomicsInDermatology #PrecisionMedicine
-
Castle Biosciences, Inc. reposted this
Save the Date for the MyPath Q&A Webinar Series! Unsure how to incorporate MyPath Melanoma into your diagnostic workflow? Questions about clinical data or utility? Need help selecting appropriate clinical scenarios for ordering? Join us for an engaging session that will involve discussions on clinical utility and supporting data, an interactive Q&A session, and a review of case studies. These sessions are open to all physicians and providers, including dermatopathologists, pathologists, dermatologists, and advanced providers. Find out more: https://hubs.la/Q02jcV1J0
-
-
We're so grateful for yet another amazing PMWC - Precision Medicine World Conference (#PMWC24)! Phenomenal educational sessions, connecting with industry colleagues, and catching up on the latest in precision medicine...already looking forward to next year!
-
-
THIS WEEK! Castle's Bob Cook helps kick off the PMWC - Precision Medicine World Conference (#PMWC24) on Wed, 1/24, when he presents "Improving Patient Care and Outcomes Using Advanced Genomics" as part of Track 3 at 2:15pm. Advanced molecular diagnostics are shifting the treatment paradigm for patients with cancers by enabling personalized and risk-aligned disease management decisions. This talk will explore the potential of #GenomicTesting in #SkinCancers to guide more informed patient care decisions that can improve patient outcomes.
-
-
NOW PUBLISHED in The Journal of Clinical and Aesthetic Dermatology (JCAD): Study finds that using DecisionDx-SCC to guide patient selection for adjuvant radiation therapy (ART), identifying patients with cutaneous squamous cell carcinoma (SCC) who can safely forgo the treatment, could result in significant savings to the healthcare system. “Above and beyond the considerable cost savings is the potential to truly improve SCC patient care by using the test’s results to provide added confidence in decisions to forgo radiation therapy when a patient’s risk of metastasis is low,” said Ally‐Khan Somani, MD, PhD, lead study author. Study highlights: https://hubs.ly/Q02gXhVx0
-
-
NEXT WEEK: We're so excited to join this "unparalleled gathering of the brightest minds and leading organizations in #PrecisionMedicine" at the Precision Medicine World Conference (#PMWC24). Castle's Senior VP of Medical, Matt Goldberg, will present "Improving Patient Care and Outcomes Using Advanced Genomics," so we hope you'll join us!
-
-
Castle was honored to ring in #NationalBiotechnologyMonth last week alongside the many distinguished companies on the #Nasdaq Biotechnology Index. DYK? Nasdaq is home to nearly 96% of US-listed #biotech companies. Castle CFO Frank Stokes took part in the virtual bell ringing. 🧬🛎️
-
-
NEW DATA: Castle presents new data this week across its dermatologic portfolio of commercially available and pipeline gene expression profile (#GEP) tests. Highlights from Castle's posters at #WinterClinical2024 - Hawaii: https://hubs.la/Q02grHf20 #DecisionDxMelanoma #DecisionDxSCC #MyPathMelanoma
-